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Metastasistothecentralnervoussystem(CNS)remainsamajorcauseofmorbidityandmortalityinpatientswithsystemiccancers.
Various crucial interactions between the brain environment and tumor cells take place during the development of the cancer at its
new location. The rapid expansion in molecular biology and genetics has advanced our knowledge of the underlying mechanisms
involved,frominvasiontoﬁnalcolonization of neworgantissues.Understandingthevariousevents occurringat eachstageshould
enable targeted drug delivery and individualized treatments for patients, with better outcomes and fewer side eﬀects. This paper
summarizes the principal molecular and genetic mechanisms that underlie the development of brain metastasis (BrM).
1.Introduction
Brain metastases are the most frequently diagnosed intracra-
nial neoplasms in adults, with an annual incidence estimated
at 200,000 cases in the USA alone [1], an incidence 10
times greater than primary brain tumors [2]. Up to 20–40%
of patients with adult systemic malignancies will develop
brain metastases in the course of their disease; about 10–
20%willbesymptomatic[3,4].Improvedtreatmentoptions
for systemic disease, along with tools that permit less
invasive screening, often when patients are asymptomatic,
have increased patient survival, paradoxically escalating
both its incidence and prevalence. A variety of systemic
malignancies can metastasize to the central nervous system
(CNS), although the majority of the lesions come from
lung cancer (40–50%) followed by breast cancer (20–30%),
melanoma (5–10%), lymphoma, and various other primary
sites like thegastrointestinal tract(4–6%) and prostate [5,6].
More than a century ago, Stephen Paget advanced his
“seed and soil” hypothesis, which suggests that the occur-
rence of brain metastases is not random, but is secondary
to certain tumor cells—“the seed”—having an attraction
for the surrounding environment—“the soil” [7]. The hy-
pothesis envisages three principles: ﬁrst, that neoplasms are
composed of heterogeneous subpopulations of cells, with
diﬀerent characteristics; second, that only a selectively “ﬁt”
subpopulation of cells will survive and multiply, invade, and
migrate to other locations; ﬁnally, that colonization depends
on tumor cell “seed” and host microenvironment “soil”
interactions [8]. According to Ewing, circulatory patterns
are responsible for the organ-speciﬁc spread between the
primary tumor and their ﬁnal destination [9]. Although
complex, the metastatic process can be broadly divided into
two main stages, the ﬁrst being the migration of tumor cells
from their primary tumor environment to various distant
tissues and the second being the colonization of these tumor
cells in their new location [10]. Underlying these two main
stages are a number of cellular hallmarks taking place during
the development and metastasis of human tumors [11]. The
variousmolecular,genetic,andepigeneticchangesthatoccur
deﬁne the multistep dissemination process of the tumor, also
known as the “metastatic cascade.”
Most BrMs occur in the cerebral hemispheres (80%),
followed by the cerebellum (15%) and the brainstem (5%),
corresponding to vascular distribution and tissue volumes
[12]. BrMs are a major cause of morbidity and mortality,
with clinical features of the metastasis corresponding to the
location, causing focal neurological deﬁcits, or presenting2 Journal of Oncology
with nonspeciﬁc central nervous system features such as
headache, cognitive impairment, and seizures [13]. The
centralnervoussystem(CNS)actsasa“safehaven,”generally
beyond the reach of nearly all chemotherapeutic agents.
The blood brain barrier (BBB) prevents the entry of most
chemotherapeutic agents, and so the brain can act as a
refuge for metastatic tumors [14]. The microenvironment of
the CNS is exceptional in having a high chloride content,
enabling tumors which prefer this environment, such as
neuroepithelial tumors like small cell cancer of the lung and
melanoma, to colonize, while potentially inhibiting invasion
by other cancer cell types without this predilection [15].
Treatments targeting metastatic intracranial disease include
surgery, whole-brain radiation therapy (WBRT), stereotactic
radiosurgery (SRS), alone or in combination with various
targeted agents, and generalized chemotherapy [16]. Follow-
ing WBRT, survival ranges from anywhere between 4 and
6 months and can be as long as 24 months [17]. Various
combinations of surgery, SRS, WBRT, and chemotherapy
have been used to improve overall survival, obtain good
clinical outcomes, and prevent recurrence of disease.
Thispaperwillfocusonmetastaticbraintumorsdescrib-
ing the hallmarks acquired in the metastatic cascade, which
ﬁnally brings cancer cells to their “safe haven” in the CNS.
The mechanisms through which cancer cells escape their
primary focus of origin, invade adjacent tissues making their
way into the microvasculature (intravasation), evade cell
death, and make their way to a distant site (extravasation),
ﬁnally proliferating and colonizing this new location, are
outlined. With further understanding of the various molecu-
lar events that occur in metastasis, future-targeted therapies
may lead to prevention or a slowdown in the development of
BrM and more eﬀective and less toxic therapy (ies).
2.The MetastaticProcess
The ability of cancer cells to sever their link to the primary
tumor site and commence the metastatic process begins
once speciﬁc functions have been acquired by an appropriate
subset of cancer cells. The multistep cascade can be grouped
into two stages: migration, which includes intravasation,
dissemination, and extravasation, and colonization (Figures
1(a) and 1(b)). We will review below the underlying patho-
biology within each stage.
2.1. Migration
2.1.1. Cellular Heterogeneity and Proliferation. The primary
tumor consists of cancer cells which are genetically hetero-
geneous and have varying potentials to metastasize. These
include the cell’s ability to invade adjacent tissues, initiate
(neo-) angiogenesis, disseminate, and adhere to new tissue
substrates, while expressing an aﬃnity for the CNS [3,
18]. Tumor cells have the ability to evade the structural
organization present in normal tissues and cells. In spite
of being exposed to various environmental pressures such
as hypoxia and nutrient deprivation, low pH, poor blood
supply, and immune and inﬂammatory mediators, a subset
of tumor cells survive these pressures with the ability to
metastasize to distant sites. Additionally, tumor cells are able
to evade growth suppressors, which limit cell growth and
proliferation, as well as circumvent inhibitors of cell prolifer-
ation such as cell cycle checkpoint and DNA damage control
systems. Tumor cells can also resist apoptosis (programmed
cell death) by the increased expression of antiapoptotic
regulators (Bcl-2, Bcl-xL), survival signals (lgf 1/2), and
downregulating proapoptotic factors (Bax, Bim, and Puma)
[19]. The primary tumor cells have the ability to acquire
genetic and epigenetic mutations such as DNA methylation
and histone modiﬁcation, allowing the ﬁttest group of cells
to survive [10, 20]. Emerging evidence also suggests that
microRNA (miRNA) species interactions with pseudogenes
may modify gene expression in cancer [21]. Various genetic
mutations result in the ability of tumor cells to commence
the proliferative process, and a number of genes associated
with this process are listed in Table 1. Clonal expansion of
these surviving ﬁt cells leads to an acquisition of further
changes, making subsequent cell lines progressively more
carcinogenic (Figure 2).
Observations within the primary tumor mass have re-
vealed the presence of heterogeneous cell lines including
cancer stem cells (CSCs), partially diﬀerentiated progenitor
cells, and fully diﬀerentiated end-stage cells; these appear to
recapitulate the same hierarchal patterns in normal tissue
types but in an uncontrolled manner [22]. Present evidence
suggests that these CSCs may be the primary drivers of the
enhanced malignant potential of primary tumors, giving
origin to their aggressive phenotypes with the ability to
degrade the extracellularmatrix (ECM),invade blood vessels
and lymph nodes, migrate, extravasate, colonize, and renew
themselves at their new locations [23, 24]. These CSCs can
reside in clusters or niches, at two or more locations within
the primary tumor cell mass [23, 24]. Thus, the key role a
CSCplaysinthemetastaticcascadecannotbeoverstated,due
to its ability to initiate tumor proliferation and “self-renew”
itselfatalternativetissuelocations. Otherobservationsreveal
that,inadditiontotheabilitiesdiscussed,theyarealsomotile
and invasive and are resilient to the apoptotic process [25].
2.1.2. Epithelial-Mesenchymal Transition (EMT). The epi-
thelial-mesenchymal transition (EMT), which is currently
at the forefront of investigation by numerous groups,
describes a temporary, reversible phenomenon wherein cells
can dediﬀerentiate, migrate to a distant focus, and then
rediﬀerentiate back to their original cell, forming a new
structure [26]. Signals activating the EMT can be intrinsic,
such as gene mutations, and extrinsic, such as growth
factor signaling. Transdiﬀerentiation appears to be initiated
by release of certain EMT-inducing transcription factors
(EMT-TFs) that transform epithelial cells into mesenchymal
derivatives, giving these cells the capacity to invade, resist
apoptosis, and disseminate [11, 27]. Transforming growth
factor β (TGFβ)[ 28], hepatocyte growth factor (HGF) [29],
epidermal growth factor (EGF), insulin-like growth factor
(IGF) [30], ﬁbroblast growth factor (FGF), and members of
the Notch signaling family [31] play a role in inducing the
EMT pathway. More recent evidence indicates that the EMT
program enables non-CSCs to derive characteristics of theJournal of Oncology 3
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Figure 1: Schematics of the process of metastasis. (a) Formation of metastatic tumor cell lines at primary sites like breast, lung, and skin
(melanoma) seen as the red nodes. Metastasis from these primary sites then spreads to the brain via the circulatory system (red arrows)
and also to adjacent sites like the liver, bone, lung, and lymph nodes (black arrows). The inset shows the primary site of melanoma cells
proliferating and migrating towards the vasculature, subsequently disseminating to secondary organ sites. (b) The metastatic tumor cells
detach from the primary site and penetrate the adjacent parenchyma to reach the blood vessels. On reaching the vessels, the cells invade and
enter the circulation (intravasation) and then disseminate within the vascular system (left half of ﬁgure). These cells eventually adhere to
secondary sites “soil” to then extravasate out of the blood vessels and for colonies of metastatic cells (right half of ﬁgure).
CSC state, which enables them to invade and disseminate
from the primary tumor to a distant, metastatic focus [32].
Some of these traits include the ability to loosen adherent
junctions, express matrix-degrading enzymes, resist apop-
tosis, and to undergo morphological conversion. Using the
EMTprogram,cancercellscan,transientlyorforlongertime
f r a m e s ,a c t i v a t et h e m s e l v e sa n da c q u i r ea t t r i b u t e sc r i t i c a lt o
survival and dissemination. To activate the EMT, a certain
amount of crosstalk has to exist between the tumor cells and
adjacent stromal cells, which are done by various EMT-TFs
and signals from within the adjacent tumor stroma [11, 32].
2.1.3. Interactions with Tumor Stroma. Progression in cancer
also involves activating a number of cells in the adjacent
stroma via paracrine signaling [33]. These stromal cells,
including endothelial cells, pericytes, ﬁbroblasts, and leuko-
cytes, provide a number of protumorigenic factors which
sustain tumor growth. The two prominent cell types are
the cancer-associated ﬁbroblasts (CAFs) and the pericytes
[34]. These cells produce growth factors, hormones, and
cytokinesthatpromotetumorproliferation.CAFsareknown
to express high amounts of TGFβ, HGF, EGF, FGF, canonical
Wnt families, and cytokines like stromal-derived factor-
(SDF-) 1α (CXL12) and interleukin-6 (IL-6) [35]. Invasion
of cancer cells can be enhanced by stromal macrophages
which supply matrix-degrading enzymes such as matrix
metalloproteinases and cysteine cathepsin protease [36].
Experimental tumor models suggest that cancer cells release
factors such as CSF-1, which stimulates macrophages in
the tumor microenvironment, with the subsequent release
of EGF, which promotes proliferation of the tumor mass
[37]. In addition, CAFs are activated by various inﬂamma-
tory mediators and induced to produce increased quanti-
ties of VEGF, FGF-2, among other cytokines and growth4 Journal of Oncology
Table 1: Genes associated with increased metastatic potential.
Genes Cancer site (primary) Role and implications OMIM
no.
Chromosome
location
RHoC Melanoma
Regulates remodeling of actin
cytoskeleton during morphogenesis
and motility. Important in tumor cell
invasion
165380 1p21-p13
LOX Breast
Head and neck cancer
Increases invasiveness of hypoxic
human cancer cells through cell matrix
adhesion and focal adhesion kinase
activity
153455 5q23.1-q23.2
VEGF
Lung
Breast
Melanoma
Colon
Angiogenic growth factor
Inhibition decreases brain metastasis
formation; reduces blood vessel
formation and cell proliferation;
increases apoptosis
192240 6p21.1
CSF1 Breast
Lung
Stimulate macrophage proliferation
and subsequent release of growth
factors
120420 1p13.3
ID1 Breast
Lung
Involved in matrix remodeling,
intracellular signaling, and
angiogenesis
600349 20q11.21
TWIST1
Breast
Gastric
Rhabdomyosarcoma
Melanoma
Hepatocellular
Causes loss of E-cadherin-mediated
cell-cell adhesion, activates
mesenchymal markers, and induces
cell motility by promoting
epithelial-mesenchymal transition
601622 7p21.1
MET R e n a lc e l lc a n c e r
Aﬀects a wide range of biological
activity depending on the cell target,
varying from mitogenesis,
morphogenesis, and motogenesis
164860 7q31.2
MMP-9
Colorectal
Breast
Melanoma
Chondrosarcoma
Extracellular matrix degradation,
tissue remodeling 120361 20q13.12
NEDD9 Melanoma Acquisition of a metastatic potential 602265 6p24.2
LEF1 Lung
Transcriptional eﬀecter—WNT
pathway; predilection for brain
metastasis
Knockdown inhibits brain metastasis,
decreases colony formation; in vitro
decreases invasion
153254 4q25
HOXB9 Lung
Breast
Homeobox gene family; critical for
embryonic segmentation and
patterning. Also a TCF4 target
Knockdown in vitro decreased
invasion and colony formation; in vivo
appears to inhibit brain metastasis
142964 17q21.32
BMP4 Lung
Colorectal
Plays an essential role in embryonic
development and may be an essential
component of the
epithelial-mesenchymal transition
112262 14q22.2
STAT3 Melanoma
Cell signaling transcription factor
Reduction suppresses brain metastasis;
decreases angiogenesis in vivo and
cellular invasion in vitro
102582 17q21.2Journal of Oncology 5
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Figure 2: Schematic of the metastatic cascade. Cascade of events taking place at the primary site during oncogenesis, illustrating the steps
creatingtheneoplasticcelllinefollowedbyclonalexpansionandsurvivaloftheﬁttestcells,becomingtheinvasiveandmetastaticphenotype.
factors, which recruits endothelial progenitor cells thereby
promoting angiogenesis [38, 39]. This dynamic stromal
environment further stresses the tumor cells, potentially
enhancing additional genomic instability, and heterogeneity
and epigenetic dysregulation [40].
2.1.4. Local Invasion. Once the phenotypically aggressive
clone has developed, spread of the tumor consists of a series
of two sequential steps: namely, invasion of the extracellular
matrix (ECM), with penetration into the vasculature and
hematogenous dissemination to the CNS. Tumor expansion
causes adjacent ECM compression and modiﬁes lymphatic
and blood vessel ﬂow, eventually leading to basement mem-
brane (BM) thinning. Combined with the various molecular
and cellular events, this leads to eventual tumor metastasis.
To reach the circulation, tumor cells must penetrate
the BM, traverse the extracellular connective tissue matrix
(ECM) tissue, and then breach the vascular basement
membrane (VBM) to enter the circulation. The process
is dependent on a number of protein complexes that
regulate cellular interactions and proteolytic enzymes, with
degradation of the ECM, which permits extravasation.
2.1.5. E-Cadherin-Catenin Complex (ECCC), Integrins,
and Other Molecules. The E-cadherin-catenin molecular
complex is essential to maintain a normal and tumoral
cytoarchitecture. It is a necessary mediator of cell-cell ad-
hesion that, among other functions, determines the polarity
of normal (and tumor) cells and their organization into
tissues [41]. Cadherin molecules are integral cell membrane
glycoproteins that interact in a homophilic manner with
one another. They have a stable extracellular fragment and
possess a cytoplasmic undercoat protein of one or more
proteins called catenins. In the process of tumor metastasis,
tumor clones become discohesive, fail to adhere to one
another, and develop a more disordered cytoarchitecture,
which allows these cells to separate from the tumor mass.
E-cadherin maintains cell adhesion by anchoring its cy-
toplasmic domain to actin cytoskeleton via α-catenin and
β-catenin. Inﬁltrating malignancies have mutations in the
genes for α-a n dβ-catenins and E-cadherin, thus decreasing
the expression of this complex. This has been correlated
with invasion, metastasis, and an unfavorable prognosis.
Furthermore, DNA hypermethylation of the promoter
region of E-cadherin can diminish or silence its expression,
thereby disturbing ECCC function, and is a common event
in many metastatic cancers [42]. N-cadherin is another
molecule connected to the cellular cytoskeleton via α-
catenin and β-catenin in a manner similar to E-cadherin.
One of the hallmarks of the EMT described above is6 Journal of Oncology
a cadherin switch, with loss of epithelial E-cadherin and gain
of mesenchymal N-cadherin functions. This induces loss of
epithelial cellular aﬃnity, while at the same time increasing
the aﬃnity of cells for the mesenchymal cells like ﬁbroblasts.
Gain-of-function mutations in N-cadherin also trigger in-
creased migration and invasion in tumors [43].
Integrins are another family of major adhesion and sig-
naling receptor proteins linking the ECM to the cellular
actincytoskeletalstructurecalledfocaladhesionsandplayan
importantroleinmediatingcellmigrationandinvasion[44].
They trigger a variety of signal transduction pathways and
regulate cytoskeletal organization, speciﬁc gene expression,
control of growth, and apoptosis. Animal models of human
nonsmallcelllungcancer(NSCLC)haveshownthatblocking
α3β1 integrin signiﬁcantly decreases brain metastasis [45].
Additionally, Carbonell et al. have shown that blocking the
β1 integrin subunit prevents adhesion to the VBM and atten-
uates the development of metastasis [46]. Integrins induce
the release of a key mediator in signaling known as focal
adhesionkinase(FAK).FAKisaubiquitouslyexpressednon-
receptor cytoplasmic tyrosine kinase, thought to play a key
role in migration and proliferation, by providing abnormal
signals for survival, EMT, invasion, and angiogenesis [47].
FAK may also play an important role in the regulation of
CSCs. Dephosphorylation and inhibition of FAK at the Y397
locus via the activated Ras (rat sarcoma) oncogene promote
tumor migration by facilitating focal adhesion at the leading
edge of tumor cells [15, 48].
The ability of tumor cells to escape the primary site
is dependent on their ability to remodel the ECM. This
remodeling occurs by breaking down or degrading the ECM
viaproteolyticenzymes,thuscreatingapathwayforinvasion.
The advancing edge of tumor cells posses the ability to carry
out this proteolytic activity by releasing signals that promote
cell proliferation and angiogenesis in the metastatic cascade.
Neurotrophins (NTs) promote brain invasion by enhancing
the production of heparinase, which is an ECM proteolytic
enzyme. Heparinase is a β-d-glucuronidase that cleaves the
heparinsulfatechainoftheECM.Itistheprominentheparin
sulfatedegradativeenzyme[49]andisknowntodestroyboth
the ECM and the BBB [3]. Evidence suggests the presence of
NTs at the tumor-brain interface in melanomas, and reports
have suggested a role for the p75 NT receptor in brain
metastasis [50].
Matrix metalloproteinases (MMPs) are members of a
family of zinc-dependent endopeptidases that function at
physiological pH and help remodeling human connective
tissue at low levels. About 25 human family members have
been identiﬁed, and they have been grouped according to
their substrate on which they act, namely, collagenases,
stromelysins,matrilysins,andgelatinases[51].Theyalsoplay
a critical role in the EMT and tumor microenvironment
[52]. Cytokines and inducers present on the surface of
tumor cells in the ECM regulate their expression. Once these
MMPs are induced and stimulated, they aid in breakdown
of type I collagen, ﬁbronectin, and laminin in the ECM [53]
and enhance tumor cell migration. MMP activity correlates
with invasiveness, metastasis, and poor prognosis [54]. In
one study of brain metastasis, MMP-2 was identiﬁed in all
metastases regardless of site of origin. Moreover, MMP-2
activity correlated inversely with survival [55]. In a murine
tumor model, the incidence of brain metastasis was reduced
by 75% when compared to the wild type following the
use of tissue inhibitor of metalloprotease1 (TIMP-1), which
suggests that inhibitors of MMPs suppress BrMs [56].
The urokinase-type plasminogen activator (uPA) system
consists of uPA, its receptor (uPAR), and plasminogen. The
uPA binds to the receptor uPA-R (CD87), the activity of
which is regulated by the action of plasminogen activator
inhibitor type 1 and 2 (PAI-1/2) on the cell membrane and
causes urokinase to convert plasminogen to plasmin. The
proteolytic activity of plasmin then degrades components
of the ECM including ﬁbrin, ﬁbronectin, proteoglycans,
and laminin. Further, plasmin activates other proteolytic
enzymes with resultant local invasion and migration [57]. As
far back as 1994, researchers have found that there is a high
level of uPA in metastatic tumors, that uPA correlates with
necrosis and edema, and that there is an inverse correlation
with a tumor’s levels of uPA and survival [58]. Additionally,
high levels of uPA and absent tissue plasminogen activator
(tPA) correlate with aggressiveness and decreased survival
[58].
More recent evidence describes the role of “invadopo-
dia,”whicharethree-dimensionalprotrusiveprocesses,com-
pared to the two-dimensional lamellipodia and ﬁlopodia,
in metastatic invasion [59]. Invadopodia appear to share a
number of structural and functional features with ﬁlopodia,
but spatially focus proteolytic secretion, remodeling the
ECM matrix and establishing tracts supporting subsequent
invasion [60]. Integrins play a major role in organizing the
components, triggering the formation of invadopodia. α3β1
activation promotes Src-dependent tyrosine phosphoryla-
tionofp190RhoGAP,viaRhoGTPasesfamily,whichactivates
invadopodiaandinvasion[61].Integrinsalsoappeartofocus
proteolytic activity to the region of these processes, as in
melanoma cells, where collagen-induced α3β1 association
with the serine protease Seprase (surface-expressed protease)
enhances the activity of matrix-degrading enzymes focally
at the invadopodia [62]. Numerous cancer cell lines such
as melanoma, breast cancer, glioma, and head and neck
cancer have shown the presence of invadopodia. A number
of other molecules, such as EGF, HGF, or TGF-β,c a n
induce their formation as well [63]. The release of tumor-
released chemokines such as CSF-1 and PIGF attract tumor-
associated macrophages (TAM) to the microenvironment,
which in turn release multiple factors stimulating invadopo-
dia [64]. In addition, a family of proteins called aquaporins
may also facilitate migration. Aquaporin-dependent tumor
angiogenesis and metastases enhance water transport in
the lamellipodia of migrating cells [65]. Studies on brain-
speciﬁc breast metastasis reveal that increased expression
of KCNMA1, a gene encoding for a big conductance type
potassium channel (BKCa) that is upregulated in breast
cancer, leads to greater invasiveness and transendothelial
migration [66].
2.1.6. Genetic Alterations. Several known tumor suppressor
genes (TSGs) that function at the level of escape andJournal of Oncology 7
migration/intravasation are worth exploring and are enu-
merated in Table 2. The best known of these is the KiSS1
gene on chromosome 1. KiSS1 encodes metastin, which is a
ligand of the orphan G protein couples receptor hOT7T175.
Lee et al. [67] have found that the forced expression of KiSS1
suppressed both melanoma and breast metastasis. Other
authors have found an inverse correlation between KiSS1
expression and melanoma progression [68].
KAI1 (CD82), a TSG on chromosome 11p11.2, regulates
adhesion, migration, growth, and diﬀerentiation of tumor
cell lines. KAI1 expression is inversely correlated with
prostate cancer progression [69]a sw e l la sb r e a s t[ 26, 27]
and melanoma metastasis [28]. Additionally, KAI1 is known
to be associated with the epidermal growth factor receptor
(EGFR), discussed later in this paper, and is thought to aﬀect
the Rho GTPase pathway [29] resulting in suppression of
lamellipodia formation and migration [30].
Hypermethylation of the TSG Drg1 inhibits both liver
metastasis and colorectal carcinoma invasion [70]. Con-
versely, overexpression of Drg1 has been linked to resistance
to irinotecan chemotherapy [71]. Finally, in a murine model
of breast cancer metastasis, the Notch signaling pathway
was found to be activated via increased Jag2 mRNA levels,
thereby,creatingacelllinethatwasbothmoremigratoryand
more invasive in collagen assays. Additionally, inactivation
of the Notch pathway signiﬁcantly decreased tumor cell
migratory and invasive activity [72]. In addition to the
suppressor genes responsible for invasion and metastasis,
there are a number of promoter genes responsible for
invasion and metastasis as well, a few of which are enu-
merated in Table 3. Genetic activation or inactivation of
promoter/suppressor genes in human cancer can be the
result of mutations, deletions, loss of heterozygosity, mul-
tiplication, and translocation [73] .T h es a m eg e n e st h a ta r e
responsible for normal cellular functioning, signaling, signal
transduction, modulating, and mediating cellular response
arefrequentlythegenesthatenhanceinvasionandmetastasis
when altered by genetic or epigenetic dysfunction [74, 75].
These changes within the primary tumor microenviron-
ment give rise to an “active seed” ready to implant itself in
a fertile environmental “soil” (Figure 3). These cellular mod-
iﬁcations enable the next steps of migration, namely, dissem-
ination and extravasation.
2.1.7. Dissemination. Once a cancer cell has breached its
microenvironment and arrived at the vasculature (brain
metastasis) or lymphatic system (other sites), the tumor cell
must survive its exposure to high shear forces and varied
stress patterns. Tumor cells respond by reenforcing their
cytoskeleton and increasing the ability to adhere to the vas-
cular wall [76]. More recent experimental evidence suggests
shear induces a paradoxical enhancement of adhesion to the
VBM via activation of Src [77] and FAK phosphorylation
seen in colon cancer cell lines [78]. On adhering to
endothelium of target tissue, the tumor cells behave like
macrophages, creating pseudopodia, and penetrating the
cell-cell junctions, driven by dynamic remodeling of the
cellular cytoskeleton [60]. There are a subset of circulating
tumor cells which maintain their physical plasticity and,
although much larger in diameter (20–30μ) than lung
capillaries (∼8μ), can survive the sieving action of lung
capillaries.Thesecellscanbefoundeithergrowingasclumps
in the lung or colonizing other organ sites [10]. Cancer cells
in circulation appear to attract platelets because of their
expressed surface tissue proteins, and these protect the cells
from the immune system [79]. Once these mobile cancer
cells get lodged in a secondary organ tissue site, there are
two pathways for colonization. One is mediated by cellular
diapedesis, extravasation, and proliferation of the tumor cell
mass, whereas the other consists of accumulation of tumor
cells within the site of obstruction in the foreign tissue
vascular bed, wherein they proliferate, prior to their rupture
into the adjacent stroma where they begin to grow [80].
2.2. Colonization
2.2.1. Organ-Speciﬁc Inﬁltration. Subsequent to intravasa-
tion and dissemination, special mechanisms are necessary
to extravasate and colonize secondary sites. The metastatic
deposits occur in certain organ tissues because of the inﬂu-
ence of hematogenous dynamics, for example, colon cancer
metastasis preferentially metastasizing to the liver because of
mesenteric circulation and large vascular sinusoids [81]. The
overexpression of the cell adhesion molecule, metadherin,
in breast cancer makes it easier for tumor cells to target
and adhere to endothelial lining in the lung parenchyma
[82], making it possible for these endothelial-adhesive
interactions to enhance the possibility of brain metastasis.
Although the exact causes of preferential metastatic sites
have not been clearly elucidated, one theory states that
direct neurotropic interactions with yet undiscovered brain
homing mechanisms result in BrM. “Vascular co-option,” a
term put forward by Carbonell et al., describes the ability of
metastatic cells to grow along the preexisting vessels much
before overt secondaries are detected. Once adherent to the
VBM, tumor cells can extravasate into the parenchyma, the
VBM thus being the “soil” for BrM (Figure 4)[ 46]. Saito
et al. demonstrated that the pia-glial membrane along the
external surface of blood vessels serves as a scaﬀold for the
angiocentric spread of metastatic cells [83].
In a mouse model of CNS metastasis, tumor cells func-
tion like macrophages within the vasculature and during
extravasation, expressing CD11b, Iba1, F4/80, CD68, CD45,
and CXCR, which are proteins normally expressed specif-
ically by macrophages [84]. The ability of tumor cells to
mimic macrophages may enable them to evade the immune
system while in the vasculature.
2.2.2. The BBB, Function of the Brain Microenvironment,
and Brain Metastasis. Passage of tumor cells across the
BBB occurs via mechanisms which have not yet been
delineated fully. Recently, three proteins that mediate breast
metastasis to the brain and lungs have been described,
namely, cyclooxygenase 2 or COX2 (also known as PTGS2),
EGFR, ligand and heparin binding epidermal growth factor
(HBEGF). These proteins facilitate extravasation through
nonfenestrated blood vessels and enhance colonization [85].
Other molecules targeting organ speciﬁc colonization may8 Journal of Oncology
Table 2: Representative metastasis and invasion suppressor genes.
Gene Cancer/metastatic tumor Function(s) of protein OMIM
no.
Chromosome
Location
NM23 Breast, colon, melanoma
A histidine kinase. Nm23
phosphorylates KSR and can lead to
decreased ERK 1/2 activation. appears
to play a role in normal development
and diﬀerentiation
156490 17q21.3
MKK4 Breast, ovarian, and
prostate
A mitogen-activated protein kinase
(MAPKK) that phosphorylates p38
and Jun (JNK) kinases
601335 17p11.2
BRMS1 Breast, melanoma Functions in gap-junction
communication 606259 11q13.1-q13.2
KiSS1 Breast, melanoma A G-protein coupled receptor ligand,
also known as metastin. 603286 1q32
KAI1 (CD82) Bladder, breast, lung,
pancreas, and prostate
Interact with beta-catenin-reptin and
histone deacetylases. It may desensitize
EGFR activity, also known as kangai
600623 11p11.2
CD44 Breast, colon, lung,
melanoma, prostate
A ni n t e g r a lc e l lm e m b r a n e
glycoprotein that aﬀects cell adhesion.
Decreased expression due in part to
hypermethylation
107269 11pter-p13
CRSP3 Melanoma
A transcriptional coactivator that may
work through the enhancer binding
factor Sp1
605042
RHOGDI2
Bladder, breast, colon,
kidney, liver, lung, and
prostate
Regulates function of Rho and Rac,
GTP-binding proteins of the Ras
superfamily
11p11.2
VDUP1 Melanoma Ad i ﬀerentiation factor via thioredoxin
inhibition 606599 1q21
PTEN/MMAC1
Breast, colon,
endometrial, germ cell,
kidney, lung, melanoma,
and thyroid
A homologue of cytoskeletal tension,
leading to invasion and metastasis
through interaction with actin
ﬁlaments at focal adhesions
601728 10q23.31
VHL
Renal cell,
pheochromocytoma,
and hemangioblastoma
Encodes protein products playing an
essential role in microtubule stability,
orientation, tumor suppression, cilia
formation, signaling of cytokines, and
extracellular matrix assembly
608537 3p25.3
TIMP2 Melanoma Protease inhibitor plays a role in
preventing excessive ECM disruption 188825 17q25.3
SMAD4 Pancreatic cancer,
colorectal, and prostate
Transcription factor, pivotal role in
signal transduction of TGFβ 600993 18q21.2
RRM1 Lung Cell cycle regulator 180410 11p15.4
PTPN11 Lung, colon, thyroid,
and melanoma
Regulates tyrosine phosphatase,
proliferation, diﬀerentiation, motility,
and apoptosis of cells
176876 12q24.1
CDH1 Gastric, breast Cellular adherens junctional protein 192090 16q22.1
CASP8 Gastric, breast, lung, and
PNETs
Apoptotic cascade via
aspartate-speciﬁc cysteine proteases 601763 2q33
Deﬁnitions: EGFR: epidermal growth factor; ERK: extracellular signal-regulated kinase; JNK: Jun-terminal kinase; KSR: kinase suppressor of Ras. OMIM no.:
Online Mendelian Inheritance in Man Identiﬁcation number (http://www.ncbi.nlm.nih.gov/), which provides detailed information and references for these
genes, their protein products, and potential functions.Journal of Oncology 9
Table 3: Representative metastasis and invasion promoter genes.
Gene Cancer/metastatic
tumor Function(s) of protein OMIM no. Chromosome
location
ERBB2 (HER2) Breast
Receptor tyrosine kinase, critical
component of IL6, and cytokine
signaling
164870 17q21.1
TIAM1
Lymphomas, renal
cell cancer, colon,
prostate, and breast
Activates Rho-like GTPase Rac1,
Tiam1Rac1 signaling which aﬀects
invasion in numerous ways
600687 21q22.1
SRC Colorectal, breast,
melanoma, and lung
Critical role in cellular signal
transduction pathways, regulating cell
division, motility, adhesion,
angiogenesis, and survival
190090 20q12-q13
S100A4
Colorectal
Breast
Gastric cancers
Increases endothelial cell motility and
induces angiogenesis, increases
invasive properties through
deregulation of the extracellular
matrix
114210 1q21
MTA1
Breast
Ovary
Lung
Gastrointestinal
Colorectal
Nucleosome remodeling and
deacetylating (NuRD) complex serves
multiple functions in cellular
signaling, chromosome remodeling
and transcription processes, that are
important in the progression,
invasion, and growth of metastatic
epithelial cells
603526 14q32.3
KRAS
Pancreatic
Lung
Colorectal
Encode GDP/GTP-binding proteins
involved in signal transduction during
cellular proliferation, diﬀerentiation,
and senescence
190070 12p12.1
HRAS
Bladder
Renal
Thyroid
Small GTPase growth promoting
factor 190020 11p15.5
Cancer cells invade by
(1) resisting apoptosis
(2) CSCs forming resistant phenotypes
(3) epithelial-mesenchymal transitions
(4) interactions with microenvironment
(5) invadopodia and aquaporins
(6) genetic alterations   
Cancer cells
ECM
Figure 3: Invasion and migration. Subsets of cancer cells at the primary site develop an invasive phenotype; survive environmental pressures
such as hypoxia and nutrient deprivation, low pH, poor blood supply, immune, and inﬂammatory mediators, gaining the ability to
metastasize to distant sites. These cancer cells can evade growth suppressors and circumvent inhibitors of cell proliferation to intravasate
and disseminate to various other sites.10 Journal of Oncology
Accumulation of cancer cells
within the site of obstruction,
colonization, and proliferation
Vascular co-option by cancer cells,
cellular diapedesis, extravasation, and
proliferation of the tumor cell mass 
Figure 4:Colonizationofmetastatictumorcellsinthebrain.Overexpressionoftheadhesionmoleculesmakesiteasyfortumorcellstotarget
and adhere to endothelial lining in the parenchyma, making it possible for these endothelial-adhesive interactions to enhance the possibility
of brain metastasis. Direct neurotropic interactions with brain homing mechanisms result in BrM. “Vascular co-option” is the ability of
metastatic cells to grow along the preexisting vessels, and once adherent to the VBM, tumor cells can extravasate into the parenchyma, the
VBM thus being the “soil” for BrM.
also be expressed by the cancer cell [86]. These molecules
include ezrin (an intracellular protein necessary for the sur-
vival of osteosarcoma cells in the lung) and serine-threonine
kinase 11 (STK11, or LKB1, a metastasis suppressor which
regulates NEDD9 in lung cancer) [87].
2.2.3. Neoangiogenesis and Proliferation. Ak e yc o m p o n e n t
of both primary and secondary (metastatic) tumor growth
at any site is angiogenesis [8]. Experimental systems, using
breast or melanoma cell lines to model BrM, have revealed
that growth may occur by utilizing preexisting vasculature,
or co-opting these vessels rather than inducing new vessel
formation (neoangiogenesis) [46, 88, 89]. Kusters et al. [90],
using a melanoma cell line in a murine metastatic brain
tumor model, showed that growth of the metastatic tumor
up to 3mm could occur without inducing the angiogenic
switch [91]. Carbonell et al. have also shown that β1 integrin,
expressed by the metastatic tumor cell line, is the key
molecule to co-opt adjacent blood vessels to the growing
tumor.
Various angiogenic factors have been scrutinized as
viable targets for treatment. Vascular endothelia growth
factor (VEGF) is the most commonly recognized angiogenic
factor. VEGF expression in breast cancer plays a role in
metastasis and inhibition with a tyrosine kinase receptor
inhibitor-reduced growthandangiogenesis [92].SSecks(Src-
suppressed C kinase substrate) has been observed to decrease
VEGFexpression.Thisproteinalsostimulatesproangiogenic
angiopoietin 1 and regulates bran angiogenesis and tight
junction creation, thus helping to regulate BBB diﬀerentia-
tion [93].
MMP-9/gelatinase B complex, a member of the MMP
f a m i l y ,a n dP A I - 1 ,au P Ac e l ls u r f a c er e c e p t o r ,m a yp l a y
roles in angiogenesis [94]. The role in angiogenesis and
uniqueness of Plexin D1 expression was explored in tumor
cells and vasculogenesis. Neoplastic cells expressed Plexin
D1 as well as tumor vasculature, while its expression in
nonneoplastic tissue was restricted to a small subset of ac-
tivatedmacrophages,whichsuggeststhatPlexinD1mayplay
a signiﬁcant role in tumor angiogenesis [95]. Overexpression
of hexokinase 2 (HK2), which plays a key role in glucose
metabolism and apoptosis, may also inﬂuence BrM in
breast and other cancers. Researchers at the National Cancer
Institute found that both mRNA and protein levels of
HK2 are elevated in brain metastatic derivative cell lines
compared to the parental cell line in vitro. Knockdown of
expression reduced cell proliferation, which implies that
HK2 contributes to the proliferation and growth of breast
cancer metastasis. Finally, increased expression of HK2 is
associated with poor survival after craniotomy [96, 97].
At least two tumor suppressor genes that function at
the proliferation level of the metastatic cascade have been
described.Theﬁrst,NM23,regulatescellgrowthbyencoding
for a nucleotide diphosphate protein kinase that interacts
with menin, a TSG encoded by MEN1 [98]. NM23 is
thought to reduce signal transduction and thereby decrease
anchorage independent colonization, invasion, and motility
[99]. In melanoma, decreased expression is correlated with
increased brain metastasis [100]. Another tumor suppressor
gene, BrMS1, located at 11q13 is altered in many melanomas
and breast cancers. BrMS1 prevents disseminated tumor cell
growth by restoring the normal gap junction phenotypeJournal of Oncology 11
and maintaining cell-to-cell communication in the primary
tumor [101]. Seraj et al. [102] found an inverse correlation
between the expression of BrMS1 and the metastatic poten-
tial in melanoma.
2.2.4. Cascade-Nonspeciﬁc Contributors to Metastasis. There
arecertainmolecularcontributionsthatcannotbeattributed
to a speciﬁc step in the cascade, either because they are active
at every level or, as in most cases, their true function is
yet to be discovered (see Tables 1 and 2). These molecular
entities are on the forefront of cancer research and are
worth addressing. Zeb-1, the zinc ﬁnger E-box homeobox
transcription factor, is overexpressed in metastatic cancers.
This overexpression leads to epithelial-mesenchymal tran-
sition and increased metastasis. Mutation of Zeb-1 leads
to decreases in the proliferation of progenitor cells in
mutant mice. This mutation may be a target for metastatic
prevention at the progenitor level [103].
Several other genetic markers have been located that
pertain to metastasis in particular. A deletion of the 4q arm
in lung (both small and nonsmall cell) metastasis to the
brain and bone has been documented [104]. Additionally, in
NSCLC, overexpression of CDH2 (N-cadherin), KIFC1,a n d
FALZ is highly predictive of metastasis to the brain in early
and advanced lung cancer. Therefore, these genes may be
used to predict a high risk of metastasis early in the diagnosis
[105]. In prostate cancer, increased expression of KLF6-
SV1, the Kruppel-like factor tumor suppressor gene, predicts
poorer survival and is correlated with increased metastasis
to the lymphatic system, the brain, and bone [106]. Finally,
overexpression of homeoprotein Six-1, a transcriptional
regulator, increased TGF-β signaling and metastasis in breast
cancer with signiﬁcantly shortened relapse times [107].
Gaining a better understanding of the role(s) of these genes
and others will be important to deeper knowledge of the
metastatic cascade.
2.2.5. Overview of microRNAs (miRNAs) and Their Emerging
Role in Oncogenesis. Recent evidence has established an
important role of microRNAs in cell and tissue develop-
ment, proliferation and motility via their ability to repress
mRNA translation or induce mRNA degradation [108].
The dysregulated expression of a single miRNA can cause
a cascade of silencing events capable of eliciting disease
development in humans, which includes cancer [109]. Breast
cancer is found to possess aberrant regulation of several
miRNAs[110].Theyalsoplayaprominentroleinexpression
of EMT-related genes. Finally, pseudogenes, which encode
RNAs that do not have to produce proteins but can compete
for microRNA binding, may play a role in tumorigenesis
and metastasis. Poliseno et al. [111]. Recently described the
functional relationship between the mRNAs produced by the
PTEN tumor suppressor gene and its pseudogene PTENP1.
PTENP1 regulates cellular levels of PTEN and can exert a
growth-suppressive role and the PTENP1 l o c u si sl o s ti n
several human tumors, including prostate and colon cancer.
They also showed that other cancer-related genes possess
pseudogenes, including oncogenic KRAS. While the role of
miRNAs and psuedogenes in metastasis is beyond the scope
of this summary, several recent, excellent reports detail this
emerging ﬁeld [21, 111, 112].
3. Conclusion
The metastatic cascade, from its initiation to its completion
in the brain, is an extremely complex, multistep process.
For patients, the progression in the metastatic cascade to
braincolonizationisbecomingbothanincreasinglytreatable
and yet simultaneously and increasingly prevalent feature of
their disease, with consequent morbidity. As more evidence
regarding the molecular and genetic factors that contribute
to the cascade appears, targeting this ominous disease with
multiple therapeutic strategies comes closer.
Knowledge of the metastatic process may lead to better
detection and treatment of brain metastases. The goal
however will be to utilize all the information gained at the
genetic and molecular level to stop cancer, at the primary
proliferative stage, preventing the initiation of the metastatic
cascade and subsequent development of brain metastasis.
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